Cargando…

Cross-reactive EBNA1 immunity targets alpha-crystallin B and is associated with multiple sclerosis

Multiple sclerosis (MS) is an inflammatory disease of the central nervous system, for which Epstein-Barr virus (EBV) infection is a likely prerequisite. Due to the homology between Epstein-Barr nuclear antigen 1 (EBNA1) and alpha-crystallin B (CRYAB), we examined antibody reactivity to EBNA1 and CRY...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Olivia G., Bronge, Mattias, Tengvall, Katarina, Akpinar, Birce, Nilsson, Ola B., Holmgren, Erik, Hessa, Tara, Gafvelin, Guro, Khademi, Mohsen, Alfredsson, Lars, Martin, Roland, Guerreiro-Cacais, André Ortlieb, Grönlund, Hans, Olsson, Tomas, Kockum, Ingrid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191428/
https://www.ncbi.nlm.nih.gov/pubmed/37196088
http://dx.doi.org/10.1126/sciadv.adg3032
Descripción
Sumario:Multiple sclerosis (MS) is an inflammatory disease of the central nervous system, for which Epstein-Barr virus (EBV) infection is a likely prerequisite. Due to the homology between Epstein-Barr nuclear antigen 1 (EBNA1) and alpha-crystallin B (CRYAB), we examined antibody reactivity to EBNA1 and CRYAB peptide libraries in 713 persons with MS (pwMS) and 722 matched controls (Con). Antibody response to CRYAB amino acids 7 to 16 was associated with MS (OR = 2.0), and combination of high EBNA1 responses with CRYAB positivity markedly increased disease risk (OR = 9.0). Blocking experiments revealed antibody cross-reactivity between the homologous EBNA1 and CRYAB epitopes. Evidence for T cell cross-reactivity was obtained in mice between EBNA1 and CRYAB, and increased CRYAB and EBNA1 CD4(+) T cell responses were detected in natalizumab-treated pwMS. This study provides evidence for antibody cross-reactivity between EBNA1 and CRYAB and points to a similar cross-reactivity in T cells, further demonstrating the role of EBV adaptive immune responses in MS development.